Quintin K. Hackshaw

Quintin K. Hackshaw serves as a Contract Specialist responsible for managing the acquisition lifecycle for complex scientific and technical services, with a primary focus on biotechnology and pharmaceutical procurement. He ensures compliance with federal acquisition regulations while facilitating timely, efficient, and mission-critical contract awards that support advanced research and manufacturing capabilities. His work centers on soliciting, evaluating, and awarding contracts for high-value biological and pharmaceutical products, as well as specialized research and development services, aligning procurement activities with national health and scientific priorities. While specific contractor names are not available, Hackshaw’s procurement patterns indicate consistent engagement with manufacturers and R&D service providers operating in the biopharmaceutical sector. He fosters relationships with vendors possessing specialized technical expertise in GMP-compliant production, clinical-grade biological synthesis, and regulatory submission support. His contracting approach emphasizes technical rigor, performance-based outcomes, and vendor qualification through rigorous source selection criteria, ensuring that awardees meet stringent quality and compliance standards. Hackshaw’s portfolio reflects a strong preference for open competition, with 100% of his acquisitions designated as “No Set-Aside.” This indicates a focus on technical merit and capability over socioeconomic categorizations, though it does not preclude participation from small businesses that meet the required technical qualifications. His approach prioritizes mission effectiveness and product integrity, aligning with agencies that require high-assurance supply chains and validated manufacturing processes. His primary NAICS focus areas include Biological Product Manufacturing, Biotechnology R&D, Pharmaceutical Preparation Manufacturing, and Medical Equipment Wholesaling, demonstrating deep expertise in life sciences procurement. He regularly handles acquisitions for active pharmaceutical ingredients, biologics, clinical trial materials, and specialized training services for regulatory compliance, positioning him as a key liaison between scientific innovation and federal acquisition policy.